$3,050,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose conbination drugs and general research and development Prescription Information Modernization Act of 2026 (PIMA) Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues Issues concerning competitive trade"
You can find more data on corporate lobbying on Quiver Quantitative.
BMY Congressional Stock Trading
Members of Congress have traded $BMY stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:
- REPRESENTATIVE MIKE KELLY sold up to $50,000 on 05/07.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
BMY Insider Trading Activity
BMY insiders have traded $BMY stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:
- CRISTIAN MASSACESI (EVP,Chief Med Offr,Head of Dev) sold 6,249 shares for an estimated $403,497
- PHIL M HOLZER (SVP and Controller) sold 500 shares for an estimated $33,750
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
BMY Hedge Fund Activity
We have seen 1,155 institutional investors add shares of BMY stock to their portfolio, and 1,151 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 71,713,442 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,132,128,528
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 67,595,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,894,834,098
- PRICE T ROWE ASSOCIATES INC /MD/ added 21,457,405 shares (+209.3%) to their portfolio in Q2 2026, for an estimated $1,236,375,676
- BLACKROCK, INC. added 8,702,106 shares (+5.1%) to their portfolio in Q2 2026, for an estimated $501,415,347
- PACER ADVISORS, INC. added 7,995,711 shares (+inf%) to their portfolio in Q2 2026, for an estimated $460,712,867
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 6,479,804 shares (+10.6%) to their portfolio in Q2 2026, for an estimated $373,366,306
- NORDEA INVESTMENT MANAGEMENT AB added 6,019,226 shares (+296.1%) to their portfolio in Q2 2026, for an estimated $346,827,802
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
